The independent source for health policy research, polling, and news.
741 - 760 of 1,300 Results
You asked about drug prices, the âCadillac taxâ on generous insurance plans and why Americans donât know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHNâs Julie Rovner to answer those questions.
Research out Wednesday indicates that guidelines are making strides in cutting back the number of pain pills doctors offer after specific types of surgeries.
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHNâs Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for âextra credit,â the panelists recommend their favorite health stories of the week.
The drug CroFab, which has been on the market since 2000, now faces competition from a drug called Anavip. But both are expensive.
A federal advisory panel says people between ages 27 and 45 may benefit from the vaccine to fight the human papillomavirus. But some public health advocates worry that the advice doesnât provide doctors and patients clear guidance about who in this large age group are good candidates for the vaccine.
Known as âauthorized generics,â in-house spinoffs of brand-name drugs quietly undermine the competition.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you donât have to.
When it comes to physician-administered infusion drugs, doctors sometimes have a financial reason for their choice and patients often arenât aware of cheaper options.
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHNâs Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
As California Attorney General Xavier Becerra cracks down on pharmaceutical companies he said paid competitors to delay generic versions of their drugs, heâs also pushing for legislation that would give his department tools to catch more of them. Itâs the first of its kind in the nation.
HHS secretary announces a preliminary plan Wednesday to allow Americans to import certain lower-cost drugs from Canada. Manufacturers were quick to criticize the plan, saying it does not guarantee the safety of drugs coming into the country.
The proposed rules would require hospitals to provide far more detail about the actual prices they charge insurers for patientsâ care.
Health officials and AIDS advocates in San Francisco have endorsed a new regimen for PrEP medication: to be taken only immediately before and after sex, thus reducing cost and potential side effects. The standard regimen is one pill a day for an open-ended period.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
The drug industry has the biggest lobbying war chest.
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHNâs Julie Rovner to discuss this, plus court actions on health issues.
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
The Americans for Tax Reform commercial takes too broad a brush against an initiative under consideration by the administration that would be part of the presidentâs promise to curb high drug prices.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Š 2026 KFF